Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

NCT07795814 is registered in ClinicalTrials.gov with Edgewise Therapeutics, Inc. as lead sponsor.

NCT NCT07795814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07795814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Lead sponsor
Edgewise Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 25, 2026
Completion date
December 31, 2027
Enrollment
90 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction